| Molecular formula | C50H73N15O11 |
|---|
| Molecular weight | 1060.2 g/mol |
|---|
| Registered trials | 150 |
|---|
| PubChem CID | 439201 |
|---|
What bradykinin is
Bradykinin is a peptide compound (PubChem CID 439201) that does not have an FDA-approved label or brand name. It is studied only in research settings, and no dosing or clinical use has been established by regulatory review.
Trial footprint
Bradykinin or closely related pathways appear in 150 registered clinical trials. A completed Phase 3 trial examined the role of the angiotensin type I receptor in regulating human coronary vascular function. Other listed studies include a recruiting Phase 2 trial pairing tenecteplase with urinary kallidinogenase for acute ischemic stroke, and a not-yet-recruiting trial comparing shock wave therapy with low level laser for chronic venous ulcers. These studies reflect ongoing research interest in bradykinin-related mechanisms rather than any confirmed treatment outcome.
FAQ
No. Bradykinin does not have an FDA-approved label, brand name, or approved indication. It is currently studied only in a research context.
Registered trials have examined bradykinin-related pathways in contexts such as coronary vascular function, acute ischemic stroke treatment, and chronic venous ulcer therapy. These are research investigations, not established treatments.
Public registries list 150 clinical trials associated with bradykinin or related mechanisms, spanning a range of phases and study statuses.
No adverse event report data is available for bradykinin in the sources reviewed, so no side effect summary can be provided at this time.
Bradykinin is a peptide with the molecular formula C50H73N15O11. It is identified in chemical databases by PubChem CID 439201.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-09-19